Acasti Pharma Inc. Investor Presentation Now Available Online

Thu Nov 10, 2011 2:09pm EST

* Reuters is not responsible for the content in this press release.

Editor's Note: There is a photo and a video associated with this release.

    On October 24, 2011 The Howard Group hosted its 3rd annual "Opportunity
Knocks" investor conference in Calgary. Tina Sampalis, President of
Acasti (TSX VENTURE:APO) provided an overview of the company to an
audience of investment advisors & private investors.

    A recording of the presentation is now available online. Click here to
view -

    Highlights on Acasti are as follows:

--  Founded 2008 - Listed 03/2011 (TSX VENTURE:APO) 
    Subsidiary of Neptune Technologies 
--  NKO Krill based Omega-3 Phospholipid products focused on natural
    cholesterol management. Decreases Triglycerides; Decreases LDL (bad
    cholesterol); Increases HDL (good cholesterol); Potential enhancer of
    Statin therapy; Potential use in Statin intolerant patients. 
--  Full access to Neptune's manufacturing & intellectual property. 
--  Very recently, Neptune & Acasti were granted an important patent, which
    is key for both companies in relation to the U.S. market. 
--  LAST WEEK Doug Loe at Byron Capital Markets gave this company a BUY
    rating with a $3.50 target price. 

    About Acasti Pharma Inc.

    Acasti Pharma is developing a product portfolio of proprietary novel
long-chain omega-3 phospholipids. Phospholipids are the major component
of cell membranes and are essential for all vital cell processes. They
are one of the principal constituents of High Density Lipoprotein (good
cholesterol) and, as such, play an important role in modulating
cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry
and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA,
which have been shown to have substantial health benefits and which are
stabilized by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular and cardiometabolic conditions
within the over-the-counter, medical food and prescription drug markets.

    About Neptune Technologies & Bioressources Inc.

    Neptune is an industry-recognized leader in the innovation, production
and formulation of science-based and clinically proven novel phospholipid
products for the nutraceutical and pharmaceutical markets. The Company
focuses on growing consumer health markets including cardiovascular,
inflammatory and neurological diseases driven by consumers taking a more
proactive approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health benefits
and to obtain regulatory approval for label health claims. Neptune is
continuously expanding its intellectual property portfolio as well as
clinical studies and regulatory approvals. Neptune's products are
marketed and distributed in over 20 countries worldwide.

    Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could cause
the actual results of the Company to be materially different from
historical results or from any future results expressed or implied by
such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates," "will," or "plans" to be uncertain
and forward-looking. The forward-looking statements contained herein are
also subject generally to other risks and uncertainties that are
described from time to time in the Company's reports filed with the
Securities and Exchange Commission and the Canadian securities

    To view the fact sheet associated with this release, please see the
following link:

    To view the photo associated with this release, please see the following

    Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this

Acasti Pharma Inc.
Tina Sampalis
+1 450.686.4555

Acasti Pharma Inc.
Xavier Harland
Chief Financial Officer

The Howard Group
Dave Burwell
(888) 221-0915

Copyright 2011, Market Wire, All rights reserved.